ReviewCell communication and signaling : CCS2026
Unlocking neuronal health: leveraging C. elegans for drug repurposing studies.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aging-related behavioral defects in Caenorhabditis elegans.Biology open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Aging affects neuronal function, leading to both structural and functional changes in the human brain. The concomitant cognitive decline and neurodegenerative diseases drive efforts to find pharmaceutical drugs to ameliorate the consequences of neuron-associated deficits during aging. C. elegans is an excellent model to combine studies of the nervous system and drug screening. C. elegans has a well-characterized and relatively simple nervous system that allows for precise mapping of neuronal circuits. Neuronal activity plays a crucial role in regulating lifespan in C. elegans. Various genetic, environmental, and pharmacological factors modulate neuronal signaling, affecting longevity by activating cell non-autonomous mechanisms in other tissues. Drug repurposing through screening approved human drugs in model organisms is an increasingly applied approach to identify off-label therapeutic effects. This review discusses research in C. elegans that applied drugs as neuromodulators with the aim to increase lifespan and healthspan. We focused on drugs with confirmed anticonvulsant, antidepressant, antipsychotic, antihypertensive, or anti-inflammatory properties. This review highlights potential mechanisms of how such drugs can exert a beneficial effect during organismal aging. Future research must intensify efforts to not only demonstrate a beneficial effect of repurposed drugs, but more importantly, to elucidate the underlying cellular responses. This will be essential for advancing selected drugs that have the potential for conserved benefit in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.